Psychiatry Research
Volume 153, Issue 3 , Pages 225-231 , 3 December 2007

Gender differences in response to antipsychotic treatment in outpatients with schizophrenia

Received 29 March 2006 ,Revised 31 July 2006 ,Accepted 20 September 2006.

References 

  1. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine. 2000;34:1878–1886
  2. Ciapparelli A, Ducci F, Carmassi C, Carlini M, Paggini R, Catena M, et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. European Archives of Psychiatry and Clinical Neuroscience. 2004;254:343–346
  3. Di Paolo T. Modulation of brain dopamine transmission by gender steroids. Annual Review of Neuroscience. 1994;5(1):27–42
  4. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, et al. Gender differences in clinical response to olanzapine compared with haloperidol. Psychiatry Research. 2002;110(1):27–37
  5. Guy G. Clinical global impression. In: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976;
  6. Hafner H, Behrens S, De Vry J, Gattaz WF. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for gender differences in schizophrenia. Psychiatry Research. 1991;38:125–134
  7. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatrica Scandinavica. 2003;107(Suppl 416):1–9
  8. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatrica Scandinavica. 2003;107:222–232
  9. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica. 2003;107(Suppl 416):16–23
  10. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of gender differences in treatment response. Canadian Journal of Psychiatry. 2001;46(6):534–541
  11. Leung A, Chue P. Gender differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica. 2000;101:3–38
  12. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry. 1994;151:1744–1752
  13. Perry PJ, Miller DD, Arnott SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. American Journal of Psychiatry. 1991;148:231–235
  14. Pinals DA, Malhotra AK, Missar CD, Picar D, Breier A. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research. 1996;22(3):215–222
  15. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first-episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry. 1999;156(4):544–549
  16. Schatzberg AF, Cole JO, DeBattista Ch. Manual of Clinical Psychopharmacology. Washington, DC: American Psychiatric Press; 2005;
  17. Seeman MV. Neuroleptic prescriptions for men and women. Social Pharmacology. 1989;3:219–236
  18. Seeman MV. The role of estrogen in schizophrenia. Journal of Psychiatry & Neuroscience. 1996;21:123–127
  19. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Gur RC. Gender differences in the clinical expression of schizophrenia. Schizophrenia Research. 1992;7:225–231
  20. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course and biological indexes in first episode schizophrenic patients. American Journal of Psychiatry. 1995;152:698–703
  21. Szymanski S, Lieberman JA, Pollack S, Kane JM, Safferman AZ, Munne R, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biological Psychiatry. 1996;39:249–254
  22. Usall J, Ochoa S, Araya S, Gost A, Busquets E Grupo NEDES. Sintomatología y género en la esquizofrenia. Actas Españolas de Psiquiatría. 2000;28(4):219–223
  23. Williams A. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208

PII: S0165-1781(06)00287-3

doi: 10.1016/j.psychres.2006.09.016

Psychiatry Research
Volume 153, Issue 3 , Pages 225-231 , 3 December 2007

Article Tools